Hussein Abdul-Hassan Tawbi MD

Hematology•Houston, TX

Assistant Professor, Medicine, University of Pittsburgh School of Medicine

Join to View Full Profile

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2005 - 2008
UPMC Medical EducationResidency, Internal Medicine, 2002 - 2005
American University of Beirut Faculty of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
GA State Medical License 2023 - 2027
TX State Medical License 2015 - 2027
AZ State Medical License 2023 - 2026
LA State Medical License 2023 - 2026
MS State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
PA State Medical License 2002 - 2016
MI State Medical License 2007 - 2008
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden Start of enrollment: 2010 Jun 01
Completed
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free Start of enrollment: 2010 Jun 01
Completed
Phase 2
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate Start of enrollment: 2012 Jan 19
Completed
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE1
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Start of enrollment: 2013 Sep 24
Completed
Phase 1, Phase 2
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Start of enrollment: 2013 Aug 23
Terminated
Phase 1
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases Start of enrollment: 2014 Aug 12
Completed
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Start of enrollment: 2014 Mar 10
COMPLETED
PHASE1
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Start of enrollment: 2015 Feb 01
Terminated
Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
COMPLETED
PHASE3
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma Start of enrollment: 2016 Dec 09
ACTIVE_NOT_RECRUITING
PHASE2
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss Start of enrollment: 2017 Jul 17
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Start of enrollment: 2019 Jul 16
RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma.
Merve Hasanov, Simin Kiany, Marie-Andrée Forget, Roland Bassett, Michael A Davies
Oncoimmunology. 2025-12-01
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.
Meredith M Regan, Paolo A Ascierto MD, Evan J Lipson, Jennell Palaia, Andriy Moshyk
Journal for Immunotherapy of Cancer. 2025-09-12
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff, Khalida Wani, Merrick I Ross
Journal of Clinical Oncology. 2025-09-10

Journal Articles

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
Metastatic Melanoma with balloon/histiocytoid Cytomorphology After Treatment with Immunotherapy: A Histologic Mimic and Diagnostic Pitfall
Michael T Tetzlaff, Priyadharsini Nagarajan, Hussein Tawbi, Victor G Prieto, Phyu P Aung, Journal of Cutaneous Pathology

Lectures

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
2019 ASCO Annual Meeting - 6/1/2019
Phase I/II study of the PI3K inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
What to Do First in Case of Melanoma Brain Metastases and Simultaneous Extracerebral Disease
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Current Insights Into Checkpoint Therapy for Central Nervous System Metastases
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

HMN 2025: How Most Sufferers with Superior Melanoma Stay Disease-Free 4 Years After Pre-Surgical ImmunotherapyJuly 12th, 2025
Most Patients with Advanced Melanoma Remain Disease-Free 4 Years After Pre-Surgical Immunotherapy, Study FindsJuly 10th, 2025
Melanoma: Neoadjuvant Immunotherapy Provides Optimal Survival ResultsSeptember 23rd, 2024
Join now to see all

Hussein Abdul-Hassan Tawbi MD

Dr. Tawbi is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.